Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis.

IF 4 3区 医学 Q1 ANDROLOGY
World Journal of Mens Health Pub Date : 2024-07-01 Epub Date: 2024-01-02 DOI:10.5534/wjmh.230155
Tzu Shuang Chen, Hui Ying Liu, Yin Lun Chang, Yao Chi Chuang, Yen Ta Chen, Yu Li Su, Chun Chieh Huang, Yen Ting Wu, Hung Jen Wang, Hao Lun Luo
{"title":"Association between Statin Use and Clinical Outcomes in Patients with <i>De Novo</i> Metastatic Prostate Cancer: A Propensity Score-weighted Analysis.","authors":"Tzu Shuang Chen, Hui Ying Liu, Yin Lun Chang, Yao Chi Chuang, Yen Ta Chen, Yu Li Su, Chun Chieh Huang, Yen Ting Wu, Hung Jen Wang, Hao Lun Luo","doi":"10.5534/wjmh.230155","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Numerous studies have produced conflicting findings regarding the efficacy of statins in prostate cancer treatment. Our objective was to examine the correlation between statin usage and clinical outcomes in Taiwanese men with <i>de novo</i> metastatic prostate cancer.</p><p><strong>Materials and methods: </strong>We identified patients diagnosed with <i>de novo</i> metastatic prostate cancer from the Chang Gung Research Database spanning the years 2007 to 2020. To minimize confounding bias, we employed the inverse probability of treatment weighting (IPTW) method. Clinical outcomes were assessed using IPTW-adjusted Kaplan-Meier curves. Multivariate Cox proportional hazard regression analysis was utilized to evaluate the association between mortality and clinical factors.</p><p><strong>Results: </strong>The study cohort comprised 1,716 statin users and 276 non-users. Patients who used statins exhibited a longer median overall survival (85.4 months compared to 58.2 months; p=0.001) and cancer-specific survival (112.6 months compared to 75.7 months; p<0.001) compared to non-users. The median time to the development of castration-resistant status was similar between statin users and non-users (p=0.069). Multivariable Cox proportional hazards regression analysis, after IPTW adjustment, demonstrated that statin use was associated with improved overall survival.</p><p><strong>Conclusions: </strong>Our study indicates that the use of statins following a <i>de novo</i> metastatic prostate cancer diagnosis enhances survival outcomes. However, statins did not appear to delay the onset of castration-resistant status. Further large-scale and long-term studies are warranted to investigate the biological effects of statins in men with prostate cancer.</p>","PeriodicalId":54261,"journal":{"name":"World Journal of Mens Health","volume":" ","pages":"630-637"},"PeriodicalIF":4.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216958/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Mens Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5534/wjmh.230155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ANDROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Numerous studies have produced conflicting findings regarding the efficacy of statins in prostate cancer treatment. Our objective was to examine the correlation between statin usage and clinical outcomes in Taiwanese men with de novo metastatic prostate cancer.

Materials and methods: We identified patients diagnosed with de novo metastatic prostate cancer from the Chang Gung Research Database spanning the years 2007 to 2020. To minimize confounding bias, we employed the inverse probability of treatment weighting (IPTW) method. Clinical outcomes were assessed using IPTW-adjusted Kaplan-Meier curves. Multivariate Cox proportional hazard regression analysis was utilized to evaluate the association between mortality and clinical factors.

Results: The study cohort comprised 1,716 statin users and 276 non-users. Patients who used statins exhibited a longer median overall survival (85.4 months compared to 58.2 months; p=0.001) and cancer-specific survival (112.6 months compared to 75.7 months; p<0.001) compared to non-users. The median time to the development of castration-resistant status was similar between statin users and non-users (p=0.069). Multivariable Cox proportional hazards regression analysis, after IPTW adjustment, demonstrated that statin use was associated with improved overall survival.

Conclusions: Our study indicates that the use of statins following a de novo metastatic prostate cancer diagnosis enhances survival outcomes. However, statins did not appear to delay the onset of castration-resistant status. Further large-scale and long-term studies are warranted to investigate the biological effects of statins in men with prostate cancer.

新发转移性前列腺癌患者使用他汀类药物与临床结果之间的关系:倾向得分加权分析
目的:关于他汀类药物在前列腺癌治疗中的疗效,许多研究得出了相互矛盾的结论。我们的目的是研究他汀类药物的使用与台湾男性新发转移性前列腺癌患者临床结果之间的相关性:我们从长庚研究数据库中找到了 2007 年至 2020 年被诊断为新发转移性前列腺癌的患者。为尽量减少混杂偏倚,我们采用了反向治疗概率加权法(IPTW)。临床结果采用经IPTW调整的Kaplan-Meier曲线进行评估。多变量考克斯比例危险回归分析用于评估死亡率与临床因素之间的关系:研究队列包括1716名他汀类药物使用者和276名非使用者。使用他汀类药物的患者的中位总生存期(85.4个月,58.2个月;P=0.001)和癌症特异性生存期(112.6个月,75.7个月;P=0.001)更长:我们的研究表明,在确诊为新发转移性前列腺癌后使用他汀类药物可提高生存率。然而,他汀类药物似乎并不能延缓阉割抵抗状态的发生。有必要进一步开展大规模的长期研究,探讨他汀类药物对男性前列腺癌患者的生物学效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Mens Health
World Journal of Mens Health Medicine-Psychiatry and Mental Health
CiteScore
7.60
自引率
2.10%
发文量
92
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信